利用磁性奈米粒子注射於腫瘤中，以及配合給予外加交流磁場使磁性奈米粒子因震盪而發熱，使腫瘤組織之溫度超過其耐熱溫度，而被破壞，此方法即為熱治療。本實驗致力於開發使用於熱治療之可調頻磁場產生器以及合成具有物理標靶特性之磁性試劑。因產熱效率皆隨著外加磁場之磁場大小、頻率與試劑之濃度的增加而上升，所以開發了能夠產生磁場大小為261 Oe、頻率 72 kHz之磁場產生器，同時利用磁性試劑混合油質的方式，使試劑有物理標靶的效果，並讓飽和磁化率提高至 10 emu/g，並測試其在磁場產生器輸出的外加磁場下能夠升溫至60℃以上，驗證了本研究開發之交流磁場產生器及磁性試劑能將組織升溫超過其耐熱溫度，將可應用於磁流體熱治療。

1. 楊謝樂, 磁性奈米粒子於生物醫學上之應用,物理雙月刊(八卷四期),697(2006)
2. H.E. Horng, Chin-Yih Hong, S.Y. Yang, H.C. Yang, S.H. Liao, C.M. Liu, and C.C. Wu,”Magnetic Nano-Particles and Their Applications in Immunoassays”, 48, 999(2006)
3. S.Y. Yang, C.B. Lan, C.H. Chen, H.E. Horng , Chin-Yih Hong, H.C. Yang, Y.K. Lai, Y.H. Lin, K.S. Teng,”Independency of Fe ions in hemoglobin on immunomagnetic reduction assay” ,321, 3266(2009)
4. S. Y. Yang, J. J. Chieh, K. W. Huang, C. C. Yang, T. C. Chen, C. S, Ho,S. F. Chang, H. H. Chen, H. E. Horng, C. Y. Hong, and H. C. Yang”Molecule-assisted nanoparticle clustering effect in immunomagnetic reduction assay” ,113, 144903 (2013)
5. J.K. Widder, A.E Senyei and D.G. Scarrpelli,“Proceeding of the Socirty for Experimental Biology & Medicine”,58,141(1978)
6. M. Suzuki, M. Shinkai, M. Yanase, A. Ito ,H. Honda, T. Kobayashi“Enhancement of Uptake of Magnetoliposomes by Magnetic Force and Hyperthermic Effect on Tumor.”, 15, 79 (1999)
7. R.T. Gordon, J.R. Hines and D. Gordon, “Intracellular hyperthermia a biophysical approach to cancer treatment via intracellular temperature and biophysical alterations”, 5,89(1979)
8. Pol-Edern Le Renard, Olivier Jordan, Antonin Faes, Alke Petri-Fink, Heinrich Hofmann, Daniel Ru¨ fenacht, Frederik Bosman, Franz Buchegger, Eric Doelker,“The in vivo performance of magnetic particle-loaded injectable, in situ gelling,carriers for the delivery of local hyperthermia” ,31, 691 (2010)
9. Hand JW, Streffer C, van Beuningen D, Vaupel P,Kallinowski F, Molls M,”Hyperthermia and the therapy of malignant tumors”, Berlin,Springer-Verlag(1987)
10. A. Jordan, P. Wust, H. Fahling, W. John, A. Hinz and R. Felix, “Inductive heating of ferrimagnetic particles and magnetic fluids: Physical evaluation of their potential for hyperthermia”, 9, 51(1993)
11. Falk MH,Issels RD,“Hyperthermia in oncology”,17,1( 2001)
12. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, “Hyperthermia in combined treatment of cancer. Lancet Oncol “;3,487( 2002)
13. I. Hilger, R. Hergt and W.A. Kaiser ,”Use of magnetic nanoparticle heating in the treatment of breast cancer, “,152,1(2005)
14. Heisterkamp, J., van Hillegersberg, R., and IJzermans, “Critical temperature and heating time for coagulation damage: Implicationsfor interstitial laser coagulation (ILC) of tumors”, 25, 257 (1999)
15. A. Ito, H. Hoinda and T. Kobayashi,”Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression.Immunother”, 55, 320 (2006)
16. M. Babincova, V. Altanerova, C. Altaner, P. Cicmance and P. Babine, “In vivo heating of magnetic nanoparticles in alternating magnetic field”, 31, 2219(2004)
17. A. Ito, M. Shinkai, H. Hoinda, T. Wakabayashi, J. Yoshida and T. Kobayashi, “Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia”,50, 515(2001)
18. A. Ito, K. Tanaka, K. Kondo, M. Shinkai, H. Hoinda, K. Matsumoto, T. Saida and T. Kobayashi,”Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma”, 94, 308(2003)
19. Wachsberger PR, Burd R, Bhala A, “Quercetin sensitizes cells in a tumour-like low pH environment to hyperthermia. “,19,507(2003)
20. Sawaji Y,Sato T, Takeuchi A, “Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumor-de rived vascular endothelial growth factor in vivo and in vitro .”, 86, 1597(2002)
21. Neel, L.:”Thermoremanent Magnetization of Fine Powders”
,25, 293(1953)
22. Blums, E., Cebers, A., and Maiorov, M.,”Magnetic Fluids”,de Gruyter, Berlin, New York(1997)
23. Berkovski, B.,”Magnetic fluids and applications handbook” ,Begell House, New York(1996)
24. Alexiou, C., Arnold, W., and Klein, R.J,”Locoregional cancer treatment with magnetic drug targeting”,60,6641(2000)
25. L . ubbe, A.S., Bergemann, C., and Riess, H.,”Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.”,56, 4686(1996)
26. Ming Ma,Ya Wu,Jie Zhou,Yongkang Sun,Yu Zhang,Ning Gu,”Size dependence of specific power absorption of Fe 3 O 4 particles in AC magnetic field”,268,33(2004)
27. A. Jordan, R. Scholz, P. Wust, H. Schirra,”Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro”, 194,185(1999)
28. A. Jordan, R. Scholz, P. Wust, H. FaK hling, R. Felix,”Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles”,201,413(1999)
29. 陳一龍,磁性奈米粒子在外加交流磁場下的產熱特性研究,台北:國立臺灣師範大學光電科技研究所(2012)
30. W.Q. Jiang, H.C. Yang, S.Y. Yang, H.E. Horng, J.C. Hung, Y.C. Chen, and C.Y,. Hong, “Preparation and properties of superparamagnetic nanoparticles with narrow size distribution and biocompatible “ ,283, 210(2004)
31. H.E. Horng, S.Y. Tang, Y.W. Huang, W.Q. Jiang, C.Y. Hong, H.C. Yang, “ Nanomagnetic particles for SQUID-based magnetically labled immunoassay” , 15, 668(2005)